All stocks Β· BAJAJHCARE
BH

Bajaj Healthcare Limited

BAJAJHCARE BSE Drug Manufacturers - Specialty & Generic Healthcare

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuti…

ISIN INE411U01027
Listed β€”
Quarters tracked 13
Filings 19 docs

About

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 Β– amino Β– 1 Β– adamantanol, N Β– boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

Key Metrics

as of Sep 2026
Market Cap1,082 Cr
P/E19.20
Div Yield0.47 %
Book Valueβ‚Ή158.00
52w Highβ‚Ή516.00
52w Lowβ‚Ή272.00
Face Valueβ‚Ή5.00

Quarterly Results

Rs. Crores Β· hover row for definition
Metric Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Sales 166.00 153.00 161.00 148.00 149.00 154.00 123.00 133.00 132.00 134.00 109.00 101.00 130.00
Expenses 137.00 130.00 131.00 121.00 124.00 143.00 101.00 109.00 108.00 118.00 89.00 82.00 108.00
Operating Profit 29.00 23.00 31.00 27.00 25.00 12.00 22.00 25.00 24.00 16.00 20.00 19.00 22.00
OPM % 17.00 15.00 19.00 18.00 16.00 8.00 18.00 18.00 19.00 12.00 18.00 19.00 17.00
Other Income 1.00 -34.00 1.00 0.00 1.00 13.00 -1.00 4.00 0.00 -36.00 -7.00 -7.00 -55.00
Depreciation 7.00 8.00 7.00 7.00 6.00 8.00 7.00 7.00 7.00 7.00 7.00 7.00 6.00
Interest 6.00 6.00 6.00 6.00 5.00 6.00 6.00 8.00 8.00 6.00 7.00 8.00 9.00
Profit before tax 16.00 -24.00 19.00 15.00 14.00 11.00 8.00 14.00 9.00 -33.00 -1.00 -3.00 -48.00
Tax % 16.00 -6.00 17.00 24.00 17.00 1.00 -39.00 30.00 23.00 -10.00 58.00 4.00 0.00
Net Profit 14.00 -23.00 16.00 11.00 12.00 11.00 12.00 9.00 7.00 -30.00 -2.00 -3.00 -48.00
EPS in Rs 4.07 -6.79 4.96 3.52 3.75 3.54 3.71 3.00 2.58 -10.84 -0.80 -1.25 -17.47

Profit & Loss

Annual Β· Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Sales 611.00543.00473.00646.00680.00657.00410.00370.00327.00231.00223.00218.00
Expenses 506.00460.00397.00534.00561.00521.00362.00327.00288.00200.00193.00189.00
Operating Profit 105.0083.0076.00112.00119.00136.0048.0043.0039.0031.0030.0029.00
OPM % 17.0015.0016.0017.0017.0021.0012.0012.0012.0013.0014.0013.00
Other Income -32.0016.00-105.00-19.001.007.007.001.002.002.000.000.00
Interest 22.0028.0030.0018.0013.008.007.008.008.008.008.008.00
Depreciation 28.0028.0028.0017.0018.0016.0012.0011.0011.0011.009.009.00
Profit before tax 23.0043.00-86.0058.0090.00119.0036.0024.0023.0014.0014.0012.00
Tax % 33.007.00-3.0025.0020.0030.0030.0033.0033.0043.0039.0037.00
Net Profit 16.0040.00-84.0043.0071.0083.0025.0016.0015.008.008.008.00
EPS in Rs 4.6812.51-30.3615.5925.8730.119.145.915.502.833.048.34
Dividend Payout % 32.008.00-3.006.006.005.000.000.005.000.000.000.00

Balance Sheet

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Equity Capital 17.0016.0014.0014.0014.0014.0014.007.007.007.007.002.00
Reserves 516.00450.00265.00354.00315.00245.00164.00122.00107.0092.0082.0078.00
Borrowings 249.00223.00333.00415.00257.00181.0091.0081.0087.0075.0081.0070.00
Other Liabilities 141.00144.00154.00115.00136.0086.0074.0057.0068.0045.0039.0038.00
Total Liabilities 923.00833.00765.00898.00721.00526.00343.00267.00268.00219.00209.00189.00
Fixed Assets 248.00238.00253.00366.00270.00208.00162.00128.00127.00128.00130.00108.00
CWIP 8.003.007.0022.0052.0057.005.001.002.000.001.001.00
Investments 0.000.000.000.000.000.005.000.000.000.000.000.00
Other Assets 667.00591.00506.00510.00399.00260.00170.00137.00140.0091.0078.0079.00
Total Assets 923.00833.00765.00898.00721.00526.00343.00267.00268.00219.00209.00189.00

Cash Flows

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Cash from Operating Activity 58.0022.0092.00-22.001.0044.0021.0025.0017.0022.0025.0028.00
Cash from Investing Activity -48.00-15.00-11.00-93.00-75.00-109.00-28.00-13.00-12.00-8.00-31.00-17.00
Cash from Financing Activity 24.00-6.00-97.00131.0062.0075.003.00-13.002.00-13.005.00-11.00
Net Cash Flow 35.000.00-16.0016.00-12.0010.00-4.000.007.000.000.000.00
Free Cash Flow 18.0010.0073.00-115.00-74.00-70.00-2.0011.005.0014.00-6.0011.00
CFO/OP % 53.0032.00138.00-10.009.0058.0062.0089.0057.0088.00100.0099.00

Ratios

Annual Β· Days / % β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Debtor Days 140.00169.00139.00110.0099.0055.0088.0077.0090.0083.0070.0086.00
Inventory Days 249.00206.00206.00199.00143.0094.0054.0045.0057.0045.0056.0050.00
Days Payable 133.00122.00128.0081.0094.0067.0080.0045.0074.0051.0046.0063.00
Cash Conversion Cycle 256.00254.00217.00228.00148.0082.0062.0077.0073.0078.0080.0073.00
Working Capital Days 119.00140.000.0027.0040.0034.0024.0012.000.00-4.00-17.00-11.00
ROCE % 11.0011.008.0014.0020.0036.0018.0016.0016.0013.0013.0016.00

Shareholding Pattern

% holding β€” latest first
Holder Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 58.59 58.29 59.19 59.19 59.19 59.19 59.19 59.19 67.74 67.74 67.73 67.69
FIIs 2.19 1.98 1.18 1.12 1.09 1.05 1.01 1.07 0.00 0.53 0.74 0.66
DIIs 1.92 2.91 2.96 2.99 3.16 2.52 2.36 1.97 0.00 0.43 0.48 0.43
Public 37.30 36.82 36.67 36.70 36.56 37.25 37.45 37.77 32.27 31.31 31.06 31.22
No. of Shareholders 41,310 38,158 37,953 38,576 35,980 35,710 32,672 31,995 32,397 32,712 29,626 28,008

Corporate Actions

10 records
ActionEx DateRecord DateRatioAmount (β‚Ή)Notes
Dividend 19 Sep 2025 19 Sep 2025 β€” 1.00
Dividend 23 Sep 2024 β€” β€” 1.00
Dividend 22 Sep 2023 β€” β€” 1.00
Dividend 22 Sep 2022 β€” β€” 1.50
Split 28 Sep 2021 29 Sep 2021 10:5 β€”
Dividend 28 Sep 2021 29 Sep 2021 β€” 0.50
Dividend 01 Dec 2020 02 Dec 2020 β€” 0.50
Dividend 01 Dec 2020 02 Dec 2020 β€” 1.25
Bonus 09 Apr 2019 10 Apr 2019 1:1 β€”
Dividend 19 Sep 2018 β€” β€” 1.00

Announcements

5 filings